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Purpose: Glaucoma is the leading cause of irreversible blindness worldwide. Most of the cases are primary open angle
glaucoma (POAG). POAG is a genetically heterogenous disease; autosomal dominance is the most frequent type of
monogenic inheritance. In this study, we identified the genotype of a MYOC mutation and investigated the phenotype of
a Chinese juvenile-onset open angle glaucoma (JOAG) pedigree (GZ.1 pedigree).
Methods: Blood samples were obtained from 24 participants. We performed sequence and gene linkage analysis in the
GZ.1 pedigree retrospectively. Comprehensive ophthalmologic examinations were performed for each family member.
Pharmacological treatment or filtering surgery was performed as needed according to the intraocular pressure (IOP) of
each individual.
Results: A Pro370Leu myocilin mutation located in exon 3 of MYOC was identified in 24 members of the GZ.1 pedigree.
Sixteen patients had juvenile-onset primary open-angle glaucoma (JOAG), and the others participating in the project had
no such genotype. Analysis of polymorphic microsatellite markers indicated that the disease in GZ.1 is autosomal dominant
inheritance. The patients in GZ.1 are characterized by early age of onset (before 35 years of age), severe clinical
presentations, and high intraocular pressure unresponsive to pharmacological treatment; requiring 89.5% of the patients
to undergo filtering surgery. Fortunately, the success rate of surgery was high. None of the patients required further medical
treatment and only one demonstrated low IOP fundus changes.
Conclusions: This is the first evidence of a founder effect for a Pro370Leu myocilin mutation in a Chinese POAG pedigree.
The family with the Pro370Leu myocilin mutation presents with juvenile-onset glaucoma. After 10 years of follow-up, it
is evident that the mutation is closely associated with the phenotype of the patients. Analysis of MYOC in JOAG patients
may enable the identification of at-risk individuals and help prevent disease progression toward the degeneration of the
optic nerve, and may also contribute to genetic counseling.
Glaucoma, one of the leading causes of blindness, is a
chronic neurodegenerative disease that will affect over 60
million  people  worldwide  by  2010  [1].  The  disease  is
characterized  by  painless,  progressive,  irreversible
degeneration  of  the  optic  nerve  and  loss  of  visual  field.
Elevated  intraocular  pressure  (IOP)  resulting  from  the
increased  aqueous  outflow  resistance  in  the  trabecular
meshwork is a major risk factor. Thus, pharmacological and
surgical treatments aim to facilitate aqueous outflow and are
essential for normalizing IOP.
Primary  open-angle  glaucoma  (POAG)  is  the  most
common form of glaucoma, especially in North America [2],
representing  more  than  half  of  all  cases.  Although  the
underlying etiology of POAG is unknown, there is evidence
that  gene  mutations  can  be  associated  with  this  disease.
According to an epidemiological survey, about 30%–56% of
patients with POAG and ocular hypertension (OHT) have a
family history, and the incidence in individuals with a first
degree relative having glaucoma is about 7–10 times higher
than in the general population [3].
Based on age at time of diagnosis, POAG is classified as
either adult- or juvenile-onset, with 35 years of age being the
boundary. Most cases of POAG follow a complex pattern of
inheritance,  while  juvenile-onset  primary  open-angle
glaucoma (JOAG) typically shows an autosomal dominant
inheritance. The phenotype of POAG is also different from
JOAG. Generally, the high intraocular pressure in POAG is
stable with pharmacological treatment, but JOAG is usually a
much more severe disease requiring surgery to avoid loss of
sight [4].
Since  the  first  POAG-correlated  mutation  gene
(trabecluar  meshwork-inducible  glucocorticoid  response/
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email: gejian@mail.sysu.edu.cnmyocilin; TIGR/MYOC) was identified in 1997 [5,6], there
have been three genes reported to be responsible for POAG,
i.e., TIGR/MYOC,OPTN (optic neuropathy inducing gene)
[7,8], and WDR36 (WD repeat domain 36 gene) [9], with
TIGR/MYOC  being  the  most  frequently  mutated  gene
[10-13]. In this case, the myocilin protein is mutated and its
abnormal function increases the resistance of the aqueous
humor  outflow,  leading  to  high  IOP.  This  results  in  the
degeneration of the optic nerve and visual field loss [14-16].
Studying the correlation between genotype and phenotype
will contribute to an improved understanding of POAG.
Here, we report the analysis of MYOC mutations and
describe  clinical  findings  in  a  large  Chinese  autosomal
dominant  JOAG  family  (GZ.1).  GZ.1  is  a  Pro370Leu
mutation encompassing 56 family members with 19 of them
exhibiting  JOAG  that  is  unresponsive  to  standard
pharmacological treatments.
METHODS
Subjects: The GZ.1 pedigree lives in Guangdong province,
China and spans 5 generations with 56 members. The proband
(III7) was tested in 1999 and diagnosed with JOAG, after
which  point  we  did  an  extended  examination  of  family
members.  We  discovered  that  affected  individuals  with
documented  bilateral  glaucoma  were  present  in  each
generation except generation V. The total number of JOAG
cases is 14 (including deceased patients; I2 and II1). During
follow up spanning the next 10 years, additional patients were
diagnosed with JOAG; between 2000 and 2002, 2 individuals
were diagnosed, and 3 more during the interval from 2003 to
2008.
In this study, we retrospectively analyze the genotype and
phenotype  of  the  GZ.1  pedigree.  The  study  was  done  in
accordance with the principles of the Declaration of Helsinki.
Informed  parental  consent,  informed  patient  consent,  and
approval  by  the  Hospital  Ethics  Committee  (Zhongshan
Ophthalmic Centre, Sun Yat-sen University) were obtained
before initiating the study.
Diagnostic criteria: The initial patient with primary open
angle glaucoma (POAG) had an intraocular pressure (IOP) of
22 mmHg or higher (in absence of IOP lowering therapy), an
open anterior chamber angle on gonioscopy, glaucomatous
optic disc features, and visual field alteration consistent with
assessed optic neuropathy. Diagnosis of juvenile-onset open
angle  glaucoma  (JOAG)  was  given  when  patients  were
younger than 35 years of age at the time of POAG diagnosis.
An IOP above 21 mmHg (without IOP lowing therapy) in the
absence of damage to the optic nerve and loss of visual field
is diagnosed as ocular hypertension (OHT).
Clinical  examination:  Comprehensive  ophthalmologic
examinations and general medical history were taken and
documented by the same two experienced doctors (Zhongshan
Ophthalmic Centre, Sun Yat-sen University). The protocol
included the best-corrected visual acuity with Snellen charts,
slit-lamp inspection of the anterior eye, IOP measurement by
Goldmann  application  tonometry,  anterior  chamber  angle
evaluation  by  gonioscopy  (Goldmann),  and  fundus
examination by 78-diopter Hruby lens including vertical and
horizontal optic cup disc ratio (C/D ratio) assessment. All
subjects  underwent  automated  visual  field  examination
(tested with Humphrey, SITA fast strategy, program 30–2).
The Optical Coherence Tomography (OCT) and color fundus
photographs of the disc and macula were tested to aid with
assessment  of  the  patient’s  visual  condition  and  stage  of
illness.
Genomic DNA extraction: Peripheral blood leukocytes were
obtained from all available family members, including 16
affected and 8 unaffected individuals. Genomic DNA was
extracted  from  peripheral  blood  as  recommended  in  the
QIAamp DNA Blood Max Kit (QIAGEN, Hilden, Germany).
Microsatellite marker analysis: A genome-wide scanning was
performed using a set of fluorescence-labeled microsatellite
markers spanning the entire human genome at approximately
10 cM intervals with the ABI PRISM Linkage Mapping Set
TABLE 1. SEQUENCES OF PRIMERS USED FOR MUTATION SCREENING OF MYOCILIN GENE.
Name Primer sequence Product
Length
(bp)
E1A 5′-TATTTTCTAAGAATCTTGCTGG-3′ 394
5′-TGGATTCATTGGGACTGG-3′
E1B 5′-GAAGCCTCACCAAGCCTC-3′ 342
5′-GCCTGGTCCAAGGTCAAT-3′
E1C 5′-CTGGAGGCCACCAAAGCT-3′ 448
5′-AGAAAGGGCAGGCAGGGA-3′
E2 5′ CATAGTCAATCCTTGGGC-3′ 392
5′-CTGCAGACCTGCTCTGACAA-3′
E3A 5′-TTTCTGAATTTACCAGGATG-3′ 426
5′-GTCAATGTCCGTGTAGCC-3′
E3B 5′-CGGACAGTTCCCGTATTC-3′ 431
5′-GCTTGGAGGCTTTTCACA-3′
E3C 5′-CAAGACCCTGACCATCCC-3′ 412
5′-TGCCCCAAATCACAAGAA-3′
Figure 1. Pedigree structure of the Chinese family with 19 affected
subjects in 5 generations. Squares indicate male subjects; circles,
female  subjects;  solid  symbols,  affected  family  members  with
JOAG; unfilled symbols, unaffected family members; diagonal line,
deceased individual. Arrow indicates the proband (III:7). According
to the distribution of the affected members, the heredity of the GZ.
1pedigree is autosomal dominant.
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1534MD-10  (Applied  Biosystems  Inc.).  DNA  samples  were
subjected to polymerase chain reaction (PCR) amplification
with a standard cycling profile of 30 cycles at 94 °C for 30 s,
55 °C for 30 s, and 72 °C for 45 s. PCR reactions were
performed in a 10 μl volume containing 0.4 mM of each
primer, 200 μM dNTPs, and 1U Taq DNA polymerase. The
PCR  products  were  separated  on  5%  denaturing
polyacrylamide  gel  in  an  Applied  Biosystems  377  DNA
sequencer (Applied Biosystems Inc.).
Linkage  analysis:  Linkage  analysis  was  performed  by
calculating two-point lod scores using the MLINK routine
from LINKAGE (ver. 5.1) software suite (provided in the
public  domain  by  the  Human  Genome  Mapping  Project
Resources  Center,  Cambridge,  UK).  LOD  scores  were
calculated with a presumed penetration rate of 95% and an
allele frequency of 0.001 for the disease allele.
Mutation  screening:  To  examine  the  probability  of  the
existence  of  disease-associated  mutations,  exon-specific
primers  were  designed  for  the  myocilin  gene  (GenBank
AB006686). PCR amplification was performed in a GeneAmp
PCR System 9700 (Applied Biosystems Inc.), with 100 ng of
Figure 3. Detection of the Pro370Leu MYOC mutation by direct
polymerase chain reaction DNA sequencing in the GZ.1 pedigree.
Representative  chromatogram  contains  sequence  from  the
noncoding  DNA  strand.  The  location  of  the  mutation  within
MYOC and the nature of the nucleotide change (C->T ) were shown
as a double peak in the heterozygous condition.
genomic DNA, 10 pmol of primers and 1U of Taq DNA
polymerase in a reaction volume of 20 μl. Primer sequences
and their PCR product sizes are given in Table 1. Samples
were subjected to a PCR amplification protocol beginning
with a denaturation step at 94 °C for 2 min, followed by 30
cycles, each consisting of a denaturation step at 94 °C for 30
s, an annealing step at about 55 °C-58 °C for 30 s, and an
extension step at 72 °C for 30 s, followed by a final extension
at 72 °C for 8 min. The amplified exons were purified and
sequenced  on  an  automated  DNA  sequencer  (model  377;
Applied Biosystems Inc.). All PCR products were sequenced
in both forward and reverse directions.
Clinical  management:  Topical  medication  was  given  to
patients with an IOP higher than 21 mmHg. Patients whose
IOP  could  not  be  controlled  with  medicine  underwent
combined  trabeculectomy.  After  surgery,  patients  were
followed closely until their IOP was stable. The assessment
included: the best-correct visual acuity, IOP, the depth of the
Figure 4. Individual III5 (top) right eye, (bottom) left eye. A: Fundus
images showing typical glaucomatous cupping of the optic disc, B:
OCT  images  showing  thinner  nerve  fiber  layer,  C:  Thin-walled
filtering blebs after filtering surgery.
Figure 2. Haplotype analysis of the GZ.1 pedigree using microsatellite markers encompassing MYOC on the long arm of chromosome 1.
MYOC resides between markers D1S196 and D1S2818. Square cells refer to males and circle cells refer to females; Filled cells are JOAG;
diagonal line, deceased; and arrow, proband. The analysis was performed in 24 informative family members including 16 affected and 8
unaffected individuals. Segregating haplotypes are shown in the rectangles.
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field, and OCT.
RESULTS
Genotype  of  the  GZ.1  pedigree:  A  MYOC  Pro370Leu
mutation was identified in 16 affected individuals of the GZ.
1 pedigree, and the rate of occurrence of mutation was 100%.
According to the distribution of the affected family members
(Figure 1), the heredity of the GZ.1 pedigree is autosomal
dominant.
Linkage analysis and Haplotype analysis demonstrated
that all affected individuals were heterozygous for this change
(Figure 2). Two-point LOD scores of markers in this region
are summarized in Table 2. A maximum LOD score of 5.46
was found for marker D1S2818 at 0.0. This marker is located
in the close vicinity of MYOC. Mutation analysis of this gene
showed a heterozygous C->T transversion at nucleotide 1,109
in exon 3, resulting in a substitution of Proline to Leucine
(Pro370Leu;  Figure  3).  This  mutation  cosegregated  in  all
affected  individuals  and  was  not  observed  in  unaffected
subjects.
Using  a  computer  sequence  alignment  program
(BLAST), amino acid sequences of MYOC obtained from
GenBank were compared among human, rat, mouse, bovine
and fugu. The comparison revealed that Pro370Leu occurred
at a highly conserved position of the myocilin gene (Table 3).
Clinical  phenotype  of  the  GZ.1  pedigree:  We  studied  an
autosomal dominant family (GZ.1 pedigree) with 17 POAG
patients; 31.48% of all family members. Among the affected
individuals, 6 of are male and 11 are female. I2 and II1 were
deceased at the time of our study, but their medical records
provided  adequate  information  concerning  their  ocular
disease.
The onset of disease with all these patients was insidious.
The average age at diagnosis was 30 years (ranging from 11
to 35 years), and the mean IOP before medical or surgical care
at the time of last follow up was 45.52±6.39 mmHg (range
from 35 to 56 mmHg). All of the patients exhibited severe
degeneration of the optic nerve and visual field defects (Figure
4). According to our investigation, most of the JOAG patients
were  unresponsive  to  antiglaucoma  medications;  filtering
surgery was often required for long-term IOP control. At the
time of the study, 17 patients (34 eyes) were operated on to
control IOP with combined trabeculectomy; none of them
needed a second operation. All of the surgeries were done in
the Zhongshan Ophthalmic Center, Sun Yat-sen University
by experienced doctors. One OHT patients (IV21) was under
treatment with medication.
After surgery, all participants obtained their target IOP;
none of them requires any medications and all appear to be
prone  to  filtering  bleb  scarring.  It  is  gratifying  that  the
postoperative  IOP  in  both  eyes  of  each  patient  has  been
controlled  at  around  10  mmHg  without  any  severe
complications, with the exception of one patient with low IOP
fundus changes.
During the 10 years of follow up with the GZ.1 pedigree,
we discovered an unusual phenomenon: with the passage of
each generation, the age of onset tended to be younger, the
pathogenetic condition tended to be more severe, and the post-
operation IOP declined further. All of generation II and III
patients  exhibited  type  II  filtering  blebs,  while  all  of
TABLE 3. COMPARISON OF AMINO ACID SEQUENCES OF MYOCILIN BETWEEN HUMAN, RAT, MOUSE, BOVIN, FUGU,
AND DARE. THE RESULT REVEALED PRO370LEU OCCURRED AT HIGHLY CONSERVED POSITIONS (BOLD P).
Protein Amino acid 370
Myoc_human ETVKAEKEIPGAGYHGQF P YSWGGYTD
Myoc_rat ETVKAEKEIPGAGYHGQF P YAWGGYTD
Myoc_mouse ETVKAEKEIPGAGYHGHF P YAWGGYTD
Myoc_bovin ETLKAEKEIPGAGYHGQF P YSWGGYTD
Myoc_fugu ESLAARLDLPHAGFHGQH P YSWGGYTD
Myoc_dare ESIAARRDLPHAGFHGQF P YSWGGYTD
TABLE 2. TWO-POINT LOD SCORES OF THE 9 DNA MARKERS IN THE GENOME-WIDE SCAN OF THE GZ.1 PEDIGREE.
Marker
Two-point LOD score values at recombination fraction (θ=)
Zmax θmax 0.0 0.1 0.2 0.3 0.4 0.5
D1S1677 -4.21 1.37 1.38 1.00 0.45 0 1.38 0.2
D1S 2878 4.82 3.98 3.05 2.03 0.93 0 4.82 0.0
D1S 382 1.52 1.25 0.96 0.65 0.32 0 1.52 0.0
D1S 1158 -1.51 1.39 1.31 0.98 0.54 0 1.39 0.1
D1S 2630 1.85 1.62 1.09 0.51 0.09 0 1.85 0.0
D1S 196 -2.37 0.50 0.52 0.34 0.11 0 0.52 0.2
D1S 218 3.00 2.88 2.38 1.65 0.78 0 3.00 0.0
D1S 2818 5.46* 4.52 3.48 2.34 1.09 0 5.46 0.0
D1S 238 -5.5 0.84 0.80 0.59 0.32 0 0.84 0.1
Microsatellite markers with an average spacing of 10 cM were used in the initial genome-wide scan. The asterisk indicates the
promising  chromosome region on 1q21-q23 within a marker presented a suggestive LOD score value of Zmax=5.46 at θ=0.00.
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4). The condition of the patients at the last follow up can be
seen in Table 4.
DISCUSSION
MYOC was the first gene in which mutations were found to
cause glaucoma. MYOC mutations account for most dominant
juvenile glaucoma cases and for approximately 2% to 4% of
unselected adult onset POAG [6]. More than 70 missense
mutations in MYOC have been identified, with the majority of
them being clustered in the conserved olfactomedin domain
of exon 3 [17,18]. In this study, we report linkage of autosomal
dominant open-angle glaucoma in a large Chinese family to a
region on chromosome 1 between D1S218 and D1S2818. A
missense mutation (Pro370Leu) in exon 3 of MYOC, one of
the candidate genes mapped in this region, was identified in
this family to cosegregate with the glaucoma phenotype. No
other sequence changes were found in the entire coding region
or splice junctions of MYOC in this family. All subjects with
a diagnosis of POAG had this mutation. It is reasonable to
decide, then, that this variant is pathogenic. The findings in
the current study enrich the evidence for MYOC as a causative
gene for POAG.
It has been observed that there might be some correlation
between  clinical  phenotypes  and  different  mutations  in
MYOC.  A  nonsense  mutation  Gln368STOP,  the  most
frequently  identified  GLC1A  mutation,  is  associated  with
late-onset POAG. The later age at diagnosis of 52 years and
the  lower  mean  peak  IOP  of  28  mmHg  suggest  that  the
Gln368STOP mutation gives rise to a more mild phenotype
than mutations associated with juvenile open-angle glaucoma
[19].  The  Thr377Met  mutation  results  in  a  more  severe
phenotype  of  the  disease  than  the  Gln368Stop  mutation.
Wiggs et al. [20] described a family in which the proband was
diagnosed  at  age  42  years  with  an  IOP  at  diagnosis  of
24 mmHg. Shimizu et al. [21] described a family with a mean
age at diagnosis of 38 years and a mean maximum IOP of
44 mmHg.
It is noteworthy that the Pro370Leu mutation has been
reported  to  be  widely  distributed  and  found  by  multiple
research  groups  in  different  locations,  with  data
demonstrating juvenile-onset glaucoma in French, Japanese,
North American, German, and Indian families [22-25]. JOAG
is  an  uncommon  autosomal  dominant  form  of  glaucoma.
Onset occurs most often before the fourth decade of life and
the phenotype is clinically more severe than late-onset POAG.
Most of the reported pedigrees linked to Pro370Leu had the
following characteristics: (1) development of POAG at a very
early age, (2) high peak levels of IOP, and (3) poor response
TABLE 4. PHENOTYPE CHARACTERISTIC OF THE 17 PATIENTS WITH JOAG FROM GZ.1 PEDIGREE AT LAST FOLLOW UP.
Subject
number Age Gender
BCVA IOP (mm hg) C/D VF
RE        LE             RE            LE              RE                      LE                  RE LE
V          H           V            H
II2 74 F 0.3 NLP 17.1 17.5 0.8 0.8 0.9 0.9 N/A N/A
II4 65 F 0.3 0.5 7 22.6 0.6 0.7 0.9 0.8 PC IZD
II6 58 F 1.0 1.2 15.6 12.1 0.4 0.5 0.6 0.7 N/A N/A
III1 59 F 0.4 0.7 16.3 13.7 0.9 0.8 0.9 0.8 N/A N/A
III4 48 F 1.5 1.2 27.3 23 0.5 0.5 0.7 0.7 N N
III5 44 M LP 1.2 19 18 1.0 1.0 0.8 0.7 N/A N/A
III7 38 F 1.5 0.1 14 15.4 0.4 0.4 1.0 0.9 N/A N/A
III8 55 F 1.0 0.6 13 16 0.5 0.6 0.95 0.85 N/A N/A
III19 35 M 1.5 1.2 15.2 17.9 0.2 0.2 0.2 0.2 N/A N/A
IV1 37 M 0.1 LP 16 19 0.9 1.0 1.0 1.0 N/A N/A
IV2 36 M 1.5 1.5 14 19 0.2 0.2 0.4 0.5 N/A N/A
IV8 26 F 1.0 1.2 11 19 1.0 1.0 0.9 0.9 IZD IZD
IV9 21 F 1.5 1.5 28 26 0.3 0.4 0.5 0.5 N N
IV10 19 M 1.5 1.2 36 37 0.9 0.8 0.55 0.6 IZD N
IV11 18 M 1.5 HM 8 7 0.5 0.4 0.3 0.3 N/A N/A
IV16 31 F 1.0 0.9 10 16 0.5 0.5 1.0 1.0 N/A N/A
IV17 32 M 0.5 0.6 8 8 0.8 0.8 0.8 0.8 N/A N/A
The Pro370Leu mutation was present in all subjects in the table. All patients in the table had undergone trabeculectomy surgery
to both eyes. Abbreviations in the table are: JOAG; juvenile open-angle glaucoma, BCVA; best-correct visual activity, RE; right
eye, LE; left eye, IOP; intraocular pressure, C/D; cup disk ratio, V; vertical, H; horizontal, VF; visual field, F; female, M; male,
OU; both eyes, N; normal, IZD; indicated inferior zone defect, NLP; no light perception, LP; light perception, and HM; hand
movement, PC; poor cooperation, N/A; unavailable.
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1537to  medical  treatment  [22-25].  The  phenotype  of  POAG
associated  with  the  Pro370Leu  mutation  was  thoroughly
assessed in our data set. The mutation carriers with glaucoma
seen in this study had a form of early adult-onset glaucoma
associated with elevated IOP. The age at diagnosis of POAG
in mutation carriers ranged from 11 to 35 years (mean 30
years).  Without  medication,  the  patients  with  mutation
presented greater median IOP of 45.52±6.39 mmHg. Most of
the patients were unresponsive to antiglaucoma medications
and filtering surgery was usually required for long-term IOP
control. Thus the Pro370Leu mutation in this Chinese family
presents a similar clinical phenotype as previously reported.
However, there are some new clinical features; the age of
onset became younger with the passage of each generation.
Carriers were 44.5 years (range, 36–56 years) in generation
II, while in generation III the mean age at diagnosis in 11 cases
was 34.4 years (range, 30–44 years). Therefore, we believe
that Pro370Leu might represent a severe and strong disease
allele in Chinese peoples, exhibiting an earlier onset and more
aggressive glaucoma phenotype.
So far, little has been known about the exact roles played
by myocilin in the development of POAG. Current studies
show that the mutant myocilin is not correctly folded into a
functional  conformation  and  accumulates  into  aggregates
inside  TM  cells  [26-28].  According  to  the  structure  of
myocilin, Pro370Leu is located within the highly conserved
OLF-domain  of  this  protein,  a  major  component  of  the
extracellular matrix of the olfactory neuroepithelium [28].
Interestingly, this region contains most the reported mutations
identified  in  patients  with  POAG.  These  factors  together
suggest that the domain is very important for the function of
this protein.
Based on our evidence, we believe that genotyping will
have predictive value, at least in cases analogous to the GZ.1
pedigree,  where  all  of  the  affected  patients  have  the
Pro370Leu mutation, which can then serve to predict JOAG.
The early detection of the at-risk individual, will allow the
adoption of optimal measures to prevent the progress of the
disease [29].
In  conclusion,  our  data  provide  strong  evidence  of  a
founder  effect  for  the  Pro370Leu  MYOC  mutation  in  a
Chinese family and show that the genetic analysis of this
mutation  could  play  a  key  role  in  the  management  of
autosomal  dominant  JOAG  in  affected  families  from  this
country. The genetic analysis of MYOC in this family could
not only be used to identify at-risk persons decades before the
disease manifests phenotypically, but also to aid in genetic
counseling. Next, we will use the genetic mutations in an
animal model to explore further the mechanisms of disease.
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